4/A: Clover Health CEO's RSU Grant Amended, Reflecting Higher Achievement

Clover Health's CEO of Medicare Advantage, Jamie L. Reynoso, reported an amended acquisition of 518,000 Class A Common Stock through restricted stock units, reflecting higher performance achievement.

Summary

• Jamie L. Reynoso, CEO of Medicare Advantage at Clover Health Investments, Corp. (CLOV), filed an amendment to a previous Form 4.
• The amendment reports the acquisition of 518,000 shares of Class A Common Stock through the settlement of restricted stock units (RSUs).
• These RSUs were earned due to the determination of performance achievement levels related to a grant awarded on October 31, 2023.
• One-half of the earned RSUs (259,000 shares) vested and were settled on September 13, 2024.
• The remaining one-half of the RSUs (259,000 shares) are scheduled to vest on October 31, 2025, contingent on continued employment.
• The transaction price for these RSUs was $0, as is typical for RSU settlements.
• Following this transaction, Jamie L. Reynoso directly beneficially owns 2,531,545 shares of Class A Common Stock.
• The amendment was filed solely to reflect the full number of RSUs that were achieved, suggesting an update to previously reported figures.

Sentiment

Score: 7

Explanation: The sentiment is positive as the amendment reflects a higher achievement of performance-based restricted stock units, indicating strong executive performance and increased insider ownership, which can be a sign of confidence.

Positives

• The amendment reflects a higher number of restricted stock units (518,000) achieved by the CEO, indicating strong performance against set targets.
• Increased beneficial ownership by a key executive (Jamie L. Reynoso now holds 2,531,545 shares) can signal management's confidence in the company's future prospects.

Future Outlook

The remaining one-half of the earned restricted stock units (259,000 shares) are scheduled to vest on October 31, 2025, provided the reporting person maintains continued employment with the company.

Management Comments

• The amendment is being filed solely to reflect the full number of RSUs that were achieved, indicating a precise update to performance-based compensation.

Industry Context

Insider transactions, particularly those involving performance-based compensation, are closely watched by the market as they can reflect management's confidence and the company's operational performance within the competitive healthcare and Medicare Advantage sectors. An amendment reflecting higher achievement could be viewed positively by investors.

Stakeholder Impact

• Shareholders may view the increased insider ownership and the achievement of performance targets by a key executive as a positive signal regarding the company's stability and future prospects.
• Employees, particularly those in leadership, may see this as an affirmation of the company's compensation structure and performance incentives.

Next Steps

• The remaining 259,000 restricted stock units are scheduled to vest on October 31, 2025, subject to Jamie L. Reynoso's continued employment.

Key Dates

Keywords

Clover Health, CLOV, Jamie L. Reynoso, SEC Form 4/A, Insider Transaction, Restricted Stock Units, RSU, Stock Award, Executive Compensation, Beneficial Ownership, Medicare Advantage